Saniona AB - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Saniona AB - Product Pipeline Review - 2016', provides an overview of the Saniona AB's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Saniona AB, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Saniona AB - The report provides overview of Saniona AB including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Saniona AB's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Saniona AB's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Saniona AB's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Saniona AB - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Saniona AB's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Saniona AB Snapshot 6 Saniona AB Overview 6 Key Information 6 Key Facts 6 Saniona AB - Research and Development Overview 7 Key Therapeutic Areas 7 Saniona AB - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Saniona AB - Pipeline Products Glance 15 Saniona AB - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Saniona AB - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Discovery Products/Combination Treatment Modalities 18 Saniona AB - Drug Profiles 19 (metoprolol + tesofensine) 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 NS-2359 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 tesofensine 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 AN-721 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 AN-788 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 AN-346 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 AN-470 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 AN-761 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 NS-9283 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecule to Agonize GABAA Alpha 2 and Alpha 3 for Neuropathic Pain 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecules to Agonize nAChR Alpha7 for Pain and Alzheimer's Disease 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecule to Activate TREK for Pain 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecule to Agonize GABA Alpha 4 Delta Receptor for Sleep Disorders, Stress and Autism 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecule to Agonize nAChR Alpha6 for Parkinson's Disease 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecule to Block TREK for Depression 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecule to Inhibit Monoamine Reuptake for Pain 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Saniona AB - Pipeline Analysis 44 Saniona AB - Pipeline Products by Target 44 Saniona AB - Pipeline Products by Route of Administration 46 Saniona AB - Pipeline Products by Molecule Type 47 Saniona AB - Pipeline Products by Mechanism of Action 48 Saniona AB - Recent Pipeline Updates 50 Saniona AB - Dormant Projects 51 Saniona AB - Discontinued Pipeline Products 52 Discontinued Pipeline Product Profiles 52 NS-2359 52 tesofensine 52 Saniona AB - Locations And Subsidiaries 53 Head Office 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Saniona AB, Key Information 6 Saniona AB, Key Facts 6 Saniona AB - Pipeline by Indication, 2016 9 Saniona AB - Pipeline by Stage of Development, 2016 10 Saniona AB - Monotherapy Products in Pipeline, 2016 11 Saniona AB - Combination Treatment Modalities in Pipeline, 2016 12 Saniona AB - Out-Licensed Products in Pipeline, 2016 13 Saniona AB - Out-Licensed Products/ Combination Treatment Modalities, 2016 14 Saniona AB - Phase II, 2016 15 Saniona AB - Phase I, 2016 16 Saniona AB - Preclinical, 2016 17 Saniona AB - Discovery, 2016 18 Saniona AB - Pipeline by Target, 2016 45 Saniona AB - Pipeline by Route of Administration, 2016 46 Saniona AB - Pipeline by Molecule Type, 2016 47 Saniona AB - Pipeline Products by Mechanism of Action, 2016 49 Saniona AB - Recent Pipeline Updates, 2016 50 Saniona AB - Dormant Developmental Projects,2016 51 Saniona AB - Discontinued Pipeline Products, 2016 52
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.